Blackstone and Alnylam Enter into a Collaboration to Accelerate the Advancement of RNAi Therapeutics

 Blackstone and Alnylam Enter into a Collaboration to Accelerate the Advancement of RNAi Therapeutics

Blackstone and Alnylam Enter into a Collaboration to Accelerate the Advancement of RNAi Therapeutics

Shots:

  • Blackstone to invest $2B in Alnylam that includes $1B in committed payments in exchange of 50% royalties and commercial milestones for inclisiran, ~$750M in a first lien senior secured term loan led by GSO, ~$150M for Alnylam’s cardiometabolic programs (vutrisiran and ALN-AGT) and ~$100M on purchase of Alnylam’s common stock
  • The transaction marks the third deal major deal for Blackstone Life Sciences, with the first one as the acquisition of Clarus in late 2018 and second as the launch of CV company, Anthos with Novartis, and established FerGene to advance bladder cancer therapy, with Ferring Pharmaceuticals
  • Inclisiran is an investigational RNAi therapeutic to treat hypercholesterolemia, currently under the US FDA’s review and has been evaluated in P-III program to reduce LDL

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Pharma Advancement

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post